Welcome Remarks

October 27, 2020

Klaus Romero, Chief Science Officer, C-Path
<table>
<thead>
<tr>
<th>Public-Private Partnerships</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active Consortia/Programs</strong></td>
</tr>
<tr>
<td>AKI/Neph</td>
</tr>
<tr>
<td>BmDR</td>
</tr>
<tr>
<td>CDRC</td>
</tr>
<tr>
<td>CPAD</td>
</tr>
<tr>
<td>CPP</td>
</tr>
<tr>
<td>CPTR</td>
</tr>
<tr>
<td>CP-SCD</td>
</tr>
<tr>
<td>DCC</td>
</tr>
<tr>
<td>D-RSC</td>
</tr>
</tbody>
</table>
# Public-Private Partnerships

<table>
<thead>
<tr>
<th>Active Consortia/Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AKI/Neph</strong> Acute Kidney Injury/Nephrotoxicity</td>
</tr>
<tr>
<td><strong>BmDR</strong> Biomarker Data Repository</td>
</tr>
<tr>
<td><strong>CDRC</strong> CURE Drug Repurposing Collaboratory</td>
</tr>
<tr>
<td><strong>CPAD</strong> Critical Path for Alzheimer’s Disease</td>
</tr>
<tr>
<td><strong>CPP</strong> Critical Path for Parkinson’s Disease</td>
</tr>
<tr>
<td><strong>CPTR</strong> Critical Path to TB Drug Regimens</td>
</tr>
<tr>
<td><strong>CP-SCD</strong> Critical Path for Sickle Cell Disease</td>
</tr>
<tr>
<td><strong>DCC</strong> Data Collaboration Center</td>
</tr>
<tr>
<td><strong>D-RSC</strong> Duchenne Muscular Dystrophy Regulatory Science Consortium</td>
</tr>
</tbody>
</table>

Please email questions to ykarten@c-path.org
# Public-Private Partnerships

<table>
<thead>
<tr>
<th>AKI/Neph</th>
<th>Acute Kidney Injury/ Nephrotoxicity</th>
<th>ePRO Consortium</th>
<th>PRO Consortium</th>
<th>PRO Consortium</th>
</tr>
</thead>
<tbody>
<tr>
<td>BmDR</td>
<td>Biomarker Data Repository</td>
<td>FA-ICD</td>
<td></td>
<td>PSTC</td>
</tr>
<tr>
<td>CDRC</td>
<td>CURE Drug Repurposing Collaboratory</td>
<td>HD-RSC</td>
<td></td>
<td>QuantMed</td>
</tr>
<tr>
<td>CPAD</td>
<td>Critical Path for Alzheimer’s Disease</td>
<td>IBD</td>
<td></td>
<td>RDCA-DAP</td>
</tr>
<tr>
<td>CPP</td>
<td>Critical Path for Parkinson’s Disease</td>
<td>INC</td>
<td></td>
<td>RD COAs</td>
</tr>
<tr>
<td>CPTR</td>
<td>Critical Path to TB Drug Regimens</td>
<td>MSOAC</td>
<td></td>
<td>T1D</td>
</tr>
<tr>
<td>CP-SCD</td>
<td>Critical Path for Sickle Cell Disease</td>
<td>PKD</td>
<td></td>
<td>TB-PACTS</td>
</tr>
<tr>
<td>DCC</td>
<td>Data Collaboration Center</td>
<td>PMD</td>
<td></td>
<td>TOMI-T1D</td>
</tr>
<tr>
<td>D-RSC</td>
<td>Duchenne Muscular Dystrophy</td>
<td>PredicTox KE</td>
<td></td>
<td>TTC</td>
</tr>
</tbody>
</table>

Please email questions to ykarten@c-path.org

www.c-path.org/cpad

CONFIDENTIAL
### Public-Private Partnerships

<table>
<thead>
<tr>
<th>AKI/Neph</th>
<th>Acute Kidney Injury/Nephrotoxicity</th>
<th>ePRO Consortium</th>
<th>PRO Consortium</th>
</tr>
</thead>
<tbody>
<tr>
<td>BmDR</td>
<td>Biomarker Data Repository</td>
<td>FA-ICD</td>
<td>PSTC</td>
</tr>
<tr>
<td>CDRC</td>
<td>CURE Drug Repurposing Collaboratory</td>
<td>HD-RSC</td>
<td>QuantMed</td>
</tr>
<tr>
<td>CPAD</td>
<td>Critical Path for Alzheimer’s Disease</td>
<td>IBD</td>
<td>RDCA-DAP</td>
</tr>
<tr>
<td>CPP</td>
<td>Critical Path for Parkinson’s Disease</td>
<td>INC</td>
<td>RD COAs</td>
</tr>
<tr>
<td>CPTR</td>
<td>Critical Path to TB Drug Regimens</td>
<td>MSOAC</td>
<td>T1D</td>
</tr>
<tr>
<td>CP-SCD</td>
<td>Critical Path for Sickle Cell Disease</td>
<td>PKD</td>
<td>TB-PACTS</td>
</tr>
<tr>
<td>DCC</td>
<td>Data Collaboration Center</td>
<td>PMD</td>
<td>TOMI-T1D</td>
</tr>
<tr>
<td>D-RSC</td>
<td>Duchenne Muscular Dystrophy Regulatory Science Consortium</td>
<td>PredicTox KE</td>
<td>TTC</td>
</tr>
</tbody>
</table>

**Active Consortia/Programs**

- **AKI/Neph**: Acute Kidney Injury/Nephrotoxicity
- **BmDR**: Biomarker Data Repository
- **CDRC**: CURE Drug Repurposing Collaboratory
- **CPAD**: Critical Path for Alzheimer’s Disease
- **CPP**: Critical Path for Parkinson’s Disease
- **CPTR**: Critical Path to TB Drug Regimens
- **CP-SCD**: Critical Path for Sickle Cell Disease
- **DCC**: Data Collaboration Center
- **D-RSC**: Duchenne Muscular Dystrophy Regulatory Science Consortium

**Consortia/Programs**

- **ePRO Consortium**: Electronic Patient-Reported Outcome Consortium
- **PRO Consortium**: Patient-Reported Outcome Consortium
- **FA-ICD**: Friedreich’s Ataxia Integrated Clinical Database
- **HD-RSC**: Huntington’s Disease Regulatory Science Consortium
- **IBD**: Inflammatory Bowel Disease
- **INC**: International Neonatal Consortium
- **MSOAC**: Multiple Sclerosis Outcome Assessment Consortium
- **PKD**: Polycystic Kidney Disease
- **PMD**: Pediatric Medical Devices
- **PredicTox KE**: PredicTox Knowledge Environment

**Other Programs**

- **PSTC**: Predictive Safety Testing Consortium
- **QuantMed**: Quantitative Medicine
- **RDCA-DAP**: Rare Disease Cures Accelerator – DAP
- **RD COAs**: Rare Disease Clinical Outcome Assessments
- **T1D**: Type 1 Diabetes Consortium
- **TB-PACTS**: TB-Platform for Aggregation of Clinical TB Studies
- **TOMI-T1D**: Trial Outcome Markers Initiative in T1D Consortium
- **TTC**: Transplant Therapeutics Consortium

Please email questions to ykarten@c-path.org
Data Sharing and Integration by Area

Clinical Data Growth

- Alzheimer's Disease
- Duchenne Muscular Dystrophy
- Friedreich's Ataxia
- Healthy Kidney Study
- Huntington's Disease
- Multiple Sclerosis
- Parkinson's Disease
- Polycystic Kidney Disease
- Tuberculosis
- Type 1 Diabetes
- Rare Diseases
- Transplant Therapeutics
- Tuberculosis
- ReSeqTB isolates: 9,215

<table>
<thead>
<tr>
<th>Clinical Data</th>
<th>Nonclinical Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies:</td>
<td>156</td>
</tr>
<tr>
<td>Subjects:</td>
<td>137,527</td>
</tr>
<tr>
<td>ReSeqTB isolates:</td>
<td>9,215</td>
</tr>
</tbody>
</table>

Please email questions to ykarten@c-path.org

CONFIDENTIAL
C-Path Knowledge Graph

Clinical area of concentration (where the core competencies have concentrated impact)

Core competencies (the scientific disciplines on which the solutions C-Path is known for are based)

Operational Excellence: Operations, Project Management, Legal, IT, HR, Finance (ensuring C-Path can function)

DDTs and other solutions may concentrate on therapeutic areas, but all are based on the core competencies

Bedrock Foundation: Unique Neutral Convener

Biomarkers and Safety Science
Clinical Outcome Assessments
Data Management and Standards
Modeling and Analytics
Regulatory/Development Science

Neuroscience
Immunology and Inflammation
Infectious Diseases
Rare/Orphan Diseases
Pediatrics
DCC and QuantMed at the service of CPAD

C-Path’s Data Collaboration Center

- Data Vault
- Curation
- Metadata Annotation
- Standardization
- Data lake
- Data Warehouse

User Friendly, Secure Cloud Interface

Data for Analysis

C-Path Quantitative Medicine Program

Other Researchers

ACTIONABLE DRUG DEVELOPMENT SOLUTIONS

Please email questions to ykarten@c-path.org

CONFIDENTIAL

www.c-path.org/cpad
DCC and QuantMed at the service of CPAD

C-Path’s Data Collaboration Center

Data for Analysis

User Friendly, Secure Cloud Interface

Interface level I: Data interrogator to help orient researchers

Interface level II: Data analysis subset generator

Interface level III: Advanced data analytics workbench

Data Vault → Curation → Metadata Annotation → Standardization → Data Warehouse → Data Lake

Clinical Trial Data
Registry Data
Natural History Data
RMT/3DT Data
Imaging Data
Translational Data
Genetic Data
Other Novel Data

Please email questions to ykarten@c-path.org

www.c-path.org/cpad
Thank You

C-Path gratefully acknowledges the support of:

FLINN Foundation and U.S. Food & Drug Administration

CONFIDENTIAL